Tea Consumption Can Lower Mortality in Chronic Kidney Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 17, 2025 -- Tea consumption offers protective effects on mortality among patients with chronic kidney disease (CKD), according to a study published online Jan. 13 in Renal Failure.
Jin Li, Ph.D., from the Guangzhou University of Chinese Medicine in China, and colleagues examined the long-term impact of tea consumption among 17,575 patients with CKD from the National Health and Nutrition Examination Survey for 1999 to 2018.
The researchers found there were 5,835 deaths during follow-up, including 1,823 cardiovascular-related deaths. Compared with never drinking tea, consuming up to four cups of tea per day was significantly associated with lower all-cause mortality among patients with CKD stage 1 to 2 (hazard ratio, 0.89; 95 percent confidence interval, 0.80 to 0.99; P = 0.04), after adjustment for confounding variables; the association between tea consumption and cardiovascular disease (CVD) mortality was not significant (hazard ratio, 0.87; 95 percent confidence interval, 0.72 to 1.05; P = 0.15). There was a dose-response effect observed, with the risks for all-cause mortality mitigated by consuming up to three to five cups of tea per day, especially in early CKD stages. In CKD stage 1 to 2, an intake of one cup per day higher of oxidized tea was associated with a 10 percent lower risk for all-cause mortality (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.99; P = 0.03). Replacing one cup of green tea with one cup of oxidized tea was associated with a significantly lower risk for all-cause and CVD mortality (hazard ratios [95 percent confidence intervals], 0.92 [0.86 to 0.98; P = 0.01] and 0.89 [0.80 to 1.00; P < 0.05], respectively) in those with CKD stage 1 to 2.
"We suggested that CKD patients limit their daily intake of tea to no more than four cups, and choose appropriate varieties and flavors, such as oxidized tea and sugar-free tea," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Worse Outcomes Seen for Unvaccinated Patients Hospitalized With COVID-19, AKI
WEDNESDAY, June 18, 2025 -- For patients hospitalized with COVID-19 infection and acute kidney injury (AKI), those who are unvaccinated have worse outcomes in terms of kidney...
Electronic Nudge Letters Do Not Improve Guideline-Directed Medical Therapy in CKD
TUESDAY, June 17, 2025 -- Neither delivery of electronic nudge letters nor letters to general practice increase uptake of guideline-directed medical therapy (GDMT) among patients...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.